Table 2.
12 months respondersa n = 17 |
Non-responders b n = 23 |
p value between a and b |
|
---|---|---|---|
Gender (male : female) | 6 : 11 | 11 : 12 | 0.43† |
Age (years), median (range) | 32 (20–59) | 32 (22–62) | 0.76 |
Weight (kg), median (IQR) | 65.3 (63.0–77.0) | 70.1 (60.5–89.3) | 0.42 |
BMI, median (IQR) | 22.31(20.2–24.8) | 26.49 (20.6–30.3) | 0.12 |
Age at diagnosis, median (range) | 15 (12–48) | 18 (8–47) | 0.59 |
Disease duration (months), median (range) | 132 (67–372) | 144 (36–576) | 0.71 |
Disease location (ileum: colon: ileocolonic) | 1 : 4 : 13 | 0 : 3 : 20 | 0.36† |
Upper intestinal involvement, n (%) | 3 (17.6) | 2 (8.7) | 0.40† |
Perianal disease, n (%) | 3 (17.6) | 5 (21.7) | 0.75† |
Disease behavior (fistulizing : non–fistulizing) | 3 : 14 | 13 : 10 | 0.013†* |
Extraintestinal manifestation, n (%) | 6 (35.3) | 12 (52.2) | 0.29† |
Previous surgery for Crohn’s disease, n (%) | 9 (52.9) | 15 (65.2) | 0.25† |
Smoker, n (%) | 1 (5.9) | 3 (15.0) | 0.46† |
Past treatment | |||
Corticosteroids, n (%) | 17 (100.0) | 22 (95.7) | 0.38† |
5-Aminosalicylates, n (%) | 16 (94.1) | 21 (91.3) | 0.74† |
Thiopurines, n (%) | 17 (100.0) | 22 (95.7) | 0.21† |
Methotrexate, n (%) | 9 (52.9) | 16 (69.6) | 0.28† |
Anti-TNF, n (%) | 16 (94.1) | 22 (95.7) | 0.83† |
(3 : 2 : 1 : 0) | (5 : 8 : 3 :1) | (5 : 14 : 3 :1) | 0.60† |
Concomitant medications | |||
Corticosteroids, n (%) | 7 (41.2) | 10 (56.5) | 0.34† |
5-Aminosalicylates, n (%) | 1 (5.9) | 1 (4.3) | 0.83† |
Harvey-Bradshaw Index, median (IQR) | 11 (6–13) | 13 (10–17) | 0.11 |
C-reactive protein (mg/dl), median (IQR) | 16 (10.5–31.5) | 34.5 (7.75–54.5) | 0.79 |
Albumin (g/dL), median (IQR) | 4.1 (3.7–4.3) | 3.7 (3.2–4.0) | 0.12 |
White blood cell count (mg/dL), median (IQR) | 9.4 (7.1–11.9) | 8.3 (6.6–10.7) | 0.49 |
Hemoglobin (mg/dL), median (IQR) | 11.3 (9.8–12.8) | 11.8 (10.2–13.1) | 0.48 |
Adverse effects, n (%) | 1 (5.9) | 5 (21.7) | 0.17† |
Fisher's exact test, all others Mann–Whitney U test.
indicates p value of <0.05.
IQR: interquartile range